Why is Sellas Life Sciences stock surging today?

Sellas Life Sciences (SLS) stock surged 245.1% in pre-market trading after its Phase 3 REGAL trial of galinpepimut-S met its primary endpoint, showing a 41% reduction in death risk. The company plans to engage with the FDA for an accelerated filing strategy. The stock was halted before resuming higher.

Original reporting
Published Nov 17, 2026, 2:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 2:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$SLS
Bullish
high confidence
Mentioned
$SLS
Relevance
9/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$SLSBullishHigh
01

Why it matters

Meeting the primary overall survival endpoint with statistical significance, coupled with a stated FDA engagement and accelerated filing plan, is a direct catalyst for valuation and trading positioning. The reported tolerability and lack of new safety signals reduce a key overhang.

02

Market read

Traders have a same-session, company-specific clinical and regulatory catalyst explaining a large pre-market surge and potential continuation risk.

03

What to watch

The article does not quantify magnitude of benefit versus specific best-available treatment details, nor does it address potential subgroup effects, durability, or how FDA may condition accelerated approval.

Relevance 9/10Novelty 9/10Timing: pre-market today, after a trading halt and immediate resumption

Background

REGAL is Sellas Life Sciences’ Phase 3 trial of galinpepimut-S (GPS), an immunotherapeutic cancer vaccine targeting AML.

Company-level read

Ticker impact

$SLSBullishHigh confidence
Context

Sellas Life Sciences shares surged pre-open after its Phase 3 REGAL trial met the primary overall survival endpoint for galinpepimut-S (GPS).

Expected impact

Likely continued upside pressure early as traders price in accelerated filing prospects, with elevated volatility risk after the initial halt/resumption.

Evidence & confidence

The article reports a statistically significant Phase 3 overall survival improvement (hazard ratio 0.59, p=0.035), removal of safety overhang, and a concrete plan to engage FDA and prepare a BLA in 1H 2027.

Market effects

Reinforces positive read-through for AML immunotherapy vaccine approaches and can lift sentiment toward clinical-stage biotech with late-stage data catalysts.

Limited direct macro linkage; broader indices described as modestly mixed/neutral.

Primarily US biotech regulatory and clinical-trial sentiment, with limited spillover beyond comparable oncology vaccine developers.

Counterpoint

A single Phase 3 endpoint and accelerated filing intent may not fully de-risk FDA review; investors could fade the move if confirmatory evidence or manufacturing/CMC questions emerge.

Key entities

  • Sellas Life Sciences

    Subject of the article; GPS Phase 3 REGAL met primary overall survival endpoint and outlined FDA accelerated filing plans.

  • Galinpepimut-S (GPS)

    Immunotherapeutic cancer vaccine targeting AML evaluated in the Phase 3 REGAL trial.

  • U.S. Food and Drug Administration (FDA)

    Company plans to engage with FDA to pursue an accelerated filing strategy and prepare a BLA in 1H 2027.

Related articles

$SLSHighAI 9/10

SELLAS Life Sciences stock soars 240% on positive cancer trial

SELLAS Life Sciences (NASDAQ:SLS) shares rose 240% after reporting positive Phase 3 trial results for its cancer vaccine, GPS. The trial met its primary endpoint, showing a 41% reduction in death risk and improved median survival. The company plans to discuss an accelerated FDA filing strategy. GPS was well-tolerated with mild to moderate side effects.

$SLSHighAI 9/10

Sellas’ GPS Cuts Death Risk By 41% In Pivotal AML Trial – Firm Eyes FDA Filing In First Half Of 2027

Sellas Life Sciences (SLS) reported that its experimental cancer vaccine, GPS, met its primary goal in a Phase 3 trial, reducing the risk of death by 41% in AML patients. The trial showed a median overall survival of 24 months vs. 14.7 months for the control group. The company plans to file for FDA approval in the first half of 2027. SLS shares rose 7.1% pre-market before trading was halted.

$SLSMedAI 8/10

Sellas' Cancer Vaccine Cuts Death Risk By 41% In Phase 3 Leukemia Trial

SELLAS Life Sciences (SLS) reported that its cancer vaccine, galinpepimut-S, met the primary survival endpoint in a Phase 3 trial for acute myeloid leukemia. The vaccine reduced death risk by 41% compared to standard treatment, with median survival of 24 months versus 14.7 months. The company plans to discuss FDA filing strategy in 2027. SLS shares rose 7.10% in pre-market trading.

$SLSHighAI 9/10

SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Ov

SELLAS Life Sciences (NASDAQ: SLS) reported positive Phase 3 REGAL trial results for its cancer vaccine, GPS, showing a 41% reduction in death risk and median OS of 24.0 months vs. 14.7 months for standard treatment. The company plans to meet with the FDA to discuss regulatory path. GPS was well-tolerated with no new safety signals. SELLAS will host a webcast to discuss results and next steps.

$SLSMedAI 8/10

SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a…

SELLAS Life Sciences Group, Inc. (SLS) filed an SEC Form 8-K — Other Events. Exhibit 99.1 SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with Acute Myeloid